Viking Therapeutics (VKTX) – FDA
-
Viking Therapeutics' weight-loss tablet shows promise in small study
-
Viking (VKTX) Climbs 10% Following Results from Phase 1 Trial of Dual GLP-1/GIP Receptor Agonist VK2735
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to VKTX Stock Lookup